admin, Author at BioHealth Innovation

Oct 03 2018

Love0

323rd Edition – October 2, 2018

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

October 2, 2018

FOUNDING MEMBER OF

Virginia Bio CEO Jeff Gallagher joins Rich Bendis on BioTalk

Jeff Gallagher, CEO of Virginia Bio sits down with BioTalk host Rich Bendis to discuss accomplishments, challenges, and initiatives in his state and the BioHealth Capital Region.

Jeff is responsible for leading the premier statewide trade group that promotes the considerable scientific and economic impact of the life sciences industry in the Commonwealth of Virginia. Prior to taking on the leadership of Virginia Bio in May 2012, Jeff was a co-founder and served as VP & General Counsel for Lyotropic Therapeutics. This small specialty pharma company used its proprietary formulation technology to create new drug products based on both NCIs and already approved API for license, further development and commercialization by mid and large pharma. Previously he practiced corporate law in Richmond, focusing on new technology company formation, international business and intellectual property transactions. He was a co-founder and longtime Chairman of the Richmond based nonprofit World Pediatric Project. He holds an A.B. in Government from Harvard, a J.D. from the University of Wisconsin Law School, and an LL.M in Public International Law from the University of Virginia School of Law. He resides with his family in the Ginter Park area of Richmond, VA.

Listen now on iTunes , Google Play , and TuneIn.

Last week to register for BioBowl…only a few spots left…and it’s free!

Join us for the 5th Annual BioBowl! You and your company team will be competing against other biotech firms to win the coveted BioBowl Trophy! But first you have to RSVP to claim your spot in the competition.

Apply Now: Immediate new opening for an NIH Entrepreneur in Residence

BioHealth Innovation, Inc. (BHI), is a Montgomery County innovation intermediary which translates market-relevant research into commercial success by bringing together management, funding, and markets. BHI is seeking an experienced life science professional with entrepreneurial and investment experience to join the BHI EIR team and serve as an Entrepreneur-in-Residence (EIR) at the National Institutes of Health (NIH). This position will report to and work closely with our lead at the NIH Office of the Director, Office of Extramural Research (OER) at the Bethesda, MD campus. The EIR will provide product, corporate and private investment strategy for companies which have SBIR/STTR awards and are ready for the next step towards commercial success.

The NIH is the world’s largest early stage biomedical investor providing nondilutive funding for US companies in the form of grants and contracts through the SBIR/STTR program. In FY19 the Congressional funds set aside for company funding exceeds $1B USD. The EIR program supports NIH interests in commercial success of its SBIR/STTR portfolio companies.

Montgomery County Awards 12 Small Business Matching Grants

Montgomery County has awarded a total of $425,000 in matching grants to 12 small companies who applied for the County’s new Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Matching Grant Program.

In order to qualify, eligible companies must have been awarded a SBIR or STTR Phase 1 or Phase II grant during the current calendar year by the National Institutes of Health (NIH), and 51 percent of research and development operations must be conducted in Montgomery County.

Save the Dates: Montgomery Innovation Academy

BHI and Launch Workplaces are co-hosting a series informational programs on topics of interest to early stage companies in Montgomery County’s innovation network. Geared toward biohealth and technology startups, these sessions are open to all start-ups in the BioHealth Capital Region (with priority on 1:1 office hours given to Montgomery County Innovation Center tenants).

Each program begins with an overview of issues related to the day’s topic with lessons learned and best practices from experts in the field and companies which have been through the process. Attendees can sign up for 1:1 meetings with the experts after the overview session to discuss their specific scenarios more in depth. Mark your calendars (more details to follow):

10/24 – CMS Reimbursement

11/28 – Legal Issues for Early Stage Companies

1/24 – Tax Implications for Startups

1/29 – Fundraising (SBIR)

2/27 – Fundraising (nonSBIR nondilutive and dilutive)

3/27 – Successful Marketing & PR Strategies

4/24 – Selling to the Government

5/15 – Pricing Factors

6/12 – Staff Recruitment and Retention

For more information/to hold your spot for one of the dates now, email BHI.

BHI Entrepreneur-in-Residence Feedback Sessions

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Schedule your feedback session with BHI Entrepreneurs-in-Residence on one of the following dates: 10/31, 12/5, 2/13, 3/20, 5/22. (30 minute blocks of time beginning at 9:00 in the morning. If the morning slots are filled, more time will be allotted beginning at 1 p.m.) Pre-registration is required; sign up here (“EIR resource”at BHI). For questions/more information, contact BHI.

Innovations in Viral Clearance – GEN

Viral clearance is not a new challenge for the biopharmaceutical industry. However, regulatory demand for better data combined with the growing recognition of the shortcomings of current virus removal and inactivation methods are fostering innovation, according to industry experts.

Rockville Innovation Center tenant, Children’s Hospital spinout ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy

ReveraGen BioPharma, Inc. recently announced the initiation and first patient enrollment in a double-blind, placebo- and prednisone-controlled clinical trial (VBP15-004) of vamorolone, a first-in-class dissociative steroidal anti-inflammatory, in Duchenne muscular dystrophy.

New Division at NIH Seeking Director

The National Institutes of Health (NIH) Office of Extramural Research (OER) provides the corporate framework for NIH research administration, ensuring scientific integrity, public accountability, and effective stewardship of the NIH extramural research portfolio. The OER is seeking a Supervisory Medical Officer (Research) or Pharm.D. or Ph.D. Clinical Research Nurse to serve as the Director of a new division with oversight for human subjects research and clinical trial policy and process implementation.

SBIR Office Hours

BioHealth Innovation sponsors quarterly office hours in Montgomery County and at Johns Hopkins Fast Forward (Fast Forward hours are for JHU innovators only).

BioHealth Capital Region innovators not located at Fast Forward can register for SBIR office hours on the following dates.

Tuesday – Nov 6, 8:00 a.m. – 12:00 p.m. – Germantown Innovation Center
Wednesday – Nov 7, 1:00 – 5:00 p.m. – Rockville Innovation Center
Tuesday – Feb 12, 8:00 a.m. – 12:00 p.m. – Germantown Innovation Center
Wednesday –Feb 13, 1:00 – 5:00 p.m. – Rockville Innovation Cente
Wednesday – May 8, 8:00 a.m. – 12:00 p.m.- Germantown Innovation Center
Thursday — May 9, 1:00 – 5:00 p.m. – Rockville Innovation Center

To register for the open sessions, click here. (BHI also will be hosting a more general SBIR overview with office hours on January 29, 2019. Mark your calendar; more details to follow.)

SBIR Funding Assistance

If you and your team are located in the BioHealth Capital Region, BHI may prepay for experts to help you improve your SBIR and other non-dilutive funding applications for biohealth related projects. Your only obligation is that if you win the award, you reimburse BHI for the consulting fees (typically $1500 or $3000) and a minimal program management fee (ten % of the prepaid consulting fee i.e. $150 or $300).

For more information contact BHI.

VC funding is on a roll in Maryland | Maryland Business News

Summer 2018 may have brought more rain than sun, but when it comes to funding at Maryland startups, things have been hot, hot, hot. With top-notch research institutions, an unparalleled technical workforce, and a network of accelerators, Maryland is a hotbed for innovation, so it’s no wonder venture capitalists want Maryland startups in their portfolio. Here’s a snapshot of companies that have recently received VC investments.

Cerecor acquires New York biopharmaceutical company for $26.6M in stock – Technical.ly Baltimore

Baltimore-based Cerecor announced the acquisition of Ichorion Therapeutics, a New York–based biopharmaceutical company.

The deal includes an all-stock transaction worth up to $26.6 million, with potential for an additional $15 million in milestones, which could be paid in cash or stock.

FDA Approves Expanded Use of Qiagen EGFR CDx in Lung Cancer | GenomeWeb

Qiagen announced today that the US Food and Drug Administration has approved the expanded use of the company’s Therascreen EGFR RGQ PCR Kit to allow its use as a companion diagnostic for Pfizer’s Vizimpro (dacomitinib) for first-line treatment of patients with non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutation.

CASI Pharmaceuticals Announces Appointment Of Chief Financial Officer

CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces the appointment of George Chi to the position of Chief Financial Officer. Dr. Wei-Wu He, Executive Chairman of CASI Pharmaceuticals, commented, “I’m very pleased to announce George’s appointment and welcome him to CASI. George joins us at an opportune time as our company prepares for the marketing and sales of our first oncology product in China. He will be integral to help transition the Company’s financial operations to commercial stage as we launch EVOMELA® and other additional products from our pipeline.”

NIH awards $5.1M to Hopkins team developing fast diagnostic tool for sexually transmitted diseases | Hub

New cases of sexually transmitted diseases are on the rise worldwide, and some strains have become resistant to the antibiotics commonly used to treat them.

With the support of a $5.1 million grant from the National Institutes of Health, Jeff Wang a professor in the Whiting School of Engineering’s Department of Mechanical Engineering and member of the school’s Institute for NanoBioTechnology, is leading a team that is creating a device that not only rapidly tests for gonorrhea, but detects if a particular bacterial strain is resistant to antibiotics.

UMD Expands Innovation and Commercialization Team – Division of Research

UM Ventures – College Park, part of the University of Maryland Division of Research, is pleased to announce the addition of new talent to its innovation and commercialization efforts: Ken Porter, director of the Office of Technology Commercialization (OTC) and Stan Smith, venture investment manager. These new hires build on UM Ventures’ strategic goal of unleashing innovation.

Saving newborn lives: Neopenda launches on Republic

Innovating medical technologies in emerging markets Medical device company with the potential to save up to 2.6M newborn lives a year

In developing countries, many hospitals are overcrowded, understaffed, and lack standard medical equipment, leading to preventable newborn deaths. Neopenda is a for-profit public benefit corporation that is developing technologies to prevent these deaths, including a wearable that captures newborn vital signs so nurses in resource-constrained hospitals can attend to babies in distress.

Cybersecurity Issues in Healthcare

When: Thursday, October 11, 20184:30 – 7:30 PM EST Where: UM BioPark801 West Baltimore StBaltimore, MD 21201

bwtech @UMBC Cyber Incubator and Anchor Ventures will co-host a special event celebrating the cybersecurity industry in Maryland. The first part of the event will include an Anchor Ventures Panel discussing “Cybersecurity Issues in Healthcare” from 4:00 PM to 5:30 PM, immediately followed by the renowned CyberTini Networking Reception from 5:30 PM to 7:30 PM. This double feature event will attract C-Level Executives and cybersecurity practitioners and will include comments by the “movers and shakers” in the cybersecurity world.

Fina Biosolutions Announces New Patent for Conjugate Vaccine Development – Business Wire

Fina Biosolutions announces that the United States Patent and Trademark Office has issued a patent for expression and purification of the conjugate vaccine protein CRM197 in E. coli. CRM197 is a key component of many vaccine formulations utilized worldwide.

BIO Praises Passage of Small Business Innovation Protection Act – Business Wire

The Biotechnology Innovation Organization applauds the House and Senate’s bipartisan passage of the Small Business Innovation Protection Act. The bill directs increased cooperation between the Small Business Administration (SBA) and the U.S. Patent and Trademark Office (PTO) to improve intellectual property protections for small businesses.

Starburst Selection Committee

We are pleased to announce a pitch event will be hosted by MITRE Corporation at the Tysons, VA campus in the Metro DC area on Wednesday, October 10th from 9am-6pm EST.

Join us to hear 10 new startups present their innovations to our ecosystem of industry experts. This will be Starburst’s annual east coast selection committee, so don’t miss out! It’s a great way to make the most of your trip for those of you who plan to be in the DC area for the AUSA conference Oct 7-10.

Roche to acquire immuno-oncology company Tusk Therapeutics – PharmaLive

Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).

Under the terms of the acquisition, Roche is paying $81 million upfront with another possible $677 million in various milestone payments.

New report for medtech industry has stark message: Tech coming for you – MedCity News

A report released this week at the annual conference of the trade association for medical device and diagnostics companies had a stark message to deliver: invest in customer-centric capabilities and digital collaborations to build personalized health solutions or die.

Biotech companies are key to the state’s innovation economy – NJTV

Across the state, nearly 120,000 scientists are developing biologically advanced materials with the potential to change the course of our health, environment and even the foods we eat. It’s expanding New Jersey’s reputation from the “medicine chest of the world” to a hub for the life sciences.

Finalists Named for 2018 Collegiate Inventors Competition – Markets Insider

The Collegiate Inventors Competition®, an annual competition that rewards innovations, discoveries and research by college and university students and their faculty advisors, announced today its 2018 Finalists.

2018 Nobel Prize in Medicine Awarded to 2 Cancer Immunotherapy Researchers – The New York Times

The 2018 Nobel Prize in Physiology or Medicine was awarded on Monday to James P. Allison of the United States and Tasuku Honjo of Japan for their work on unleashing the immune system’s ability to attack cancer, a breakthrough in developing new cancer treatments.